1. Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC

3. Why worry about Pharmacokinetics (PK) and Drug – Drug Interactions (DDIs) in managing HCV patients?

4. Interaction due to Enzyme Inhibition: Increased systemic exposure

5. Interaction due to Enzyme Induction: Decreased systemic exposure

6. The importance of Cytochrome P450 (CYP) enzymes

7. Drugs can be metabolised in the Gastrointestinal tract and Liver

8. Drugs can be transported in the Gastrointestinal tract and Liver

9. Understanding the disposition of the DAAs

10. Telaprevir DDIs

11. Telaprevir increases exposure to CYP3A substrates: Perpetrator

12. Telaprevir increases exposure to CYP3A substrates

13. Telaprevir decreases exposure to other CYP substrates

14. Telaprevir decreases total but not unbound methadone concentrations.

15. Enzyme inducing agents reduce telaprevir exposure: Victim

16. Interactions with Boosted PIs

17. Telaprevir: DDIs with HIV antiretrovirals

18. Key CROI abstract

19. Boceprevir DDIs

20. Boceprevir increases exposure to CYP3A substrates

21. Boceprevir decreases exposure to other CYP substrates

22. Boceprevir exposure is decreased by efavirenz

23. Interaction of Boceprevir and Boosted HIV PIs

24. Boceprevir does not alter the PK of Raltegravir

25. Key CROI abstract

26. DAA Clinical Pharmacology

27. Contraindications with telaprevir and boceprevir

28. Drug Survey: Outline

29. Management of Drug-Drug Interactions

31. Disposition of Antidepressants

32. DAAs and Lipid Lowering Agents

33. Implications for clinical practice

34. TMC435 (Simeprivir)

35. TMC435 (Simeprivir) Interactions

36. BMS

37. DAA clinical pharmacology: conclusions

38. Thank you